Baseline characteristics
| Age ≥65 years | Age <65 years | P value | |
| (n=245) | (n=579) | ||
| Demographics and medical history | |||
| Age, years | 69.2±3.9 | 53.7±6.6 | <0.001 |
| Female | 50 (20.4) | 128 (22.1) | 0.59 |
| Caucasian | 234 (95.5) | 529 (91.4)* | 0.04 |
| Higher education (>13 years) | 95 (38.8) | 236 (40.8) | 0.64 |
| Relationship (married or cohabiting) | 198 (80.8) | 471 (81.3) | 0.85 |
| Index event | |||
| ST-segment elevation myocardial infarction | 77 (31.4) | 266 (45.9) | <0.001 |
| Non-ST-segment elevation myocardial infarction | 91 (37.1) | 200 (34.5) | 0.47 |
| Unstable angina | 28 (11.4) | 40 (6.9) | 0.04 |
| Stable angina requiring revascularisation | 49 (20.0) | 73 (12.6) | 0.01 |
| Treatment | |||
| Percutaneous coronary intervention | 180 (73.5) | 459 (79.3) | 0.08 |
| Coronary artery bypass surgery | 35 (14.3) | 52 (9.0) | 0.03 |
| Medication only | 30 (12.2) | 68 (11.7)* | 0.82 |
| Medication prescription | |||
| Antiplatelet/anticoagulation agents | 244 (99.6) | 578 (99.8) | 0.51 |
| Beta-blockers | 209 (85.3) | 493 (85.1) | 1.00 |
| ACE inhibiter/ARB | 190 (77.6) | 423 (73.1) | 0.19 |
| Lipid-lowering drugs | 239 (97.6) | 559 (96.5) | 0.52 |
| Previous cardiovascular disease | |||
| Myocardial infarction | 62 (25.3) | 121 (20.9) | 0.17 |
| Percutaneous coronary intervention | 49 (20.0) | 79 (13.6) | 0.03 |
| Coronary artery bypass surgery | 19 (7.8) | 12 (2.1) | <0.001 |
| Stroke | 12 (4.9) | 14 (2.4) | 0.08 |
| Peripheral artery disease | 24 (9.8) | 15 (2.6) | <0.001 |
| No known history of cardiovascular disease | 134 (54.7)* | 402 (69.4) | <0.001 |
Values are mean±SD or n (%).
*Difference between intervention and control group after randomisation, p<0.05.
ARB, angiotensin II receptor blockers.